Related references
Note: Only part of the references are listed.Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin
S. Pehrsson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Methodological Rigor in Preclinical Cardiovascular Studies Targets to Enhance Reproducibility and Promote Research Translation
F. Daniel Ramirez et al.
CIRCULATION RESEARCH (2017)
Unraveling the Pharmacokinetic Interaction of Ticagrelor and MEDI2452 (Ticagrelor Antidote) by Mathematical Modeling
J. Almquist et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)
Structural and functional characterization of a specific antidote for ticagrelor
Andrew Buchanan et al.
BLOOD (2015)
Antidotes progress for new oral clotbusters
Elie Dolgin
NATURE BIOTECHNOLOGY (2015)
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Marc P. Bonaca et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The bioanalytical challenge of determining unbound concentration and protein binding for drugs
Lars B. Nilsson
BIOANALYSIS (2013)
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial
Richard C. Becker et al.
EUROPEAN HEART JOURNAL (2011)
Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS/MS
Henrik Sillen et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2011)
Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry
Henrik Sillen et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2010)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Inhibition of platelet aggregation by AZD6140, A reversible oral P2Y12 receptor antagonist, compared with clopidogral in patients with acute coronary syndrome
Robert F. Storey et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
From ATP to AZD6140:: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis
Brian Springthorpe et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Share Paper
